Cargando…
Gender differences in response and remission rates among patients receiving esketamine
INTRODUCTION: Depressive disorders are among the leading causes of disability. The lifetime risk for developing clinically significant depression is estimated around 15%. Multiple studies have found female-male ratio of 2:1 across nations and cultures. The reason for this marked difference is still...
Autores principales: | Guterman, A. T., Feffer, K., Gershi, A. Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596366/ http://dx.doi.org/10.1192/j.eurpsy.2023.385 |
Ejemplares similares
-
Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023) -
How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021) -
Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial
por: Reif, A., et al.
Publicado: (2023) -
The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021) -
Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)